Kenneth Janzon
Technik-/Wissenschafts-/F&E-Leiter bei Nordvacc Läkemedel AB
Vermögen: 439 236 $ am 30.04.2024
Aktive Positionen von Kenneth Janzon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Nordvacc Läkemedel AB
Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Karriereverlauf von Kenneth Janzon
Ehemalige bekannte Positionen von Kenneth Janzon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
INTERVACC AB | Direktor/Vorstandsmitglied | 01.01.2001 | 14.06.2018 |
Gründer | 01.01.2001 | 14.06.2018 | |
Independent Dir/Board Member | 01.01.2001 | - |
Statistik
International
Schweden | 3 |
Operativ
Director/Board Member | 1 |
Founder | 1 |
Independent Dir/Board Member | 1 |
Sektoral
Health Technology | 2 |
Distribution Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
INTERVACC AB | Health Technology |
Private Unternehmen | 1 |
---|---|
Nordvacc Läkemedel AB
Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Distribution Services |
- Börse
- Insiders
- Kenneth Janzon
- Erfahrung